-
Publication Venue For
-
Declines in health insurance among cancer survivors since the 2016 US elections..
21:e517.
2020
-
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial..
21:1066-1076.
2020
-
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study..
21:808-820.
2020
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study..
21:519-530.
2020
-
Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study..
21:421-435.
2020
-
Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE)..
21:436-445.
2020
-
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial..
20:1710-1718.
2019
-
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial..
20:1370-1385.
2019
-
Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study..
20:1420-1431.
2019
-
Nanoparticle augmentation of radiotherapy in sarcoma..
20:1046-1048.
2019
-
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium..
20:e378-e389.
2019
-
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial..
20:1011-1022.
2019
-
Ovarian cancer: time to move beyond one size fits all..
20:754-755.
2019
-
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial..
20:636-648.
2019
-
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study..
20:581-590.
2019
-
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study..
20:518-530.
2019
-
Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration..
20:14-15.
2019
-
Patient-reported outcome monitoring in a routine paediatric oncology setting: challenges and opportunities..
20:19-20.
2019
-
Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort..
19:1590-1601.
2018
-
Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial..
19:1516-1529.
2018
-
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial..
19:1504-1515.
2018
-
Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial..
19:1394-1403.
2018
-
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology..
19:e240-e251.
2018
-
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial..
19:510-520.
2018
-
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study..
19:486-496.
2018
-
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply..
18:e709-e710.
2017
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial..
18:1688-1700.
2017
-
Reducing the global cancer burden among young adults..
18:1554-1555.
2017
-
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial..
18:1493-1501.
2017
-
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial..
18:1317-1326.
2017
-
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial..
18:1373-1385.
2017
-
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study..
18:1182-1191.
2017
-
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial..
18:1089-1103.
2017
-
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study..
18:1061-1075.
2017
-
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial..
18:732-742.
2017
-
Drug development in prostate cancer: time to embrace RECIST?.
18:419-421.
2017
-
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study..
18:230-240.
2017
-
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study..
18:31-41.
2017
-
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data..
18:132-142.
2017
-
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study..
18:42-51.
2017
-
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial..
17:1558-1568.
2016
-
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial..
17:1590-1598.
2016
-
Patient safety and institutional review boards in multi-institutional dose escalation or expansion trials..
17:1190-1191.
2016
-
Hypofractionation for prostate cancer: tested and proven..
17:1020-1022.
2016
-
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial..
17:883-895.
2016
-
Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database..
17:966-975.
2016
-
Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial..
17:590-599.
2016
-
Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort..
17:567-576.
2016
-
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis..
17:484-495.
2016
-
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial..
17:378-388.
2016
-
Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study..
16:1659-1666.
2015
-
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study..
16:1099-1110.
2015
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial..
16:908-918.
2015
-
Surgery versus SABR for resectable non-small-cell lung cancer..
16:e370-e371.
2015
-
Docetaxel for advanced prostate cancer: how early to start?.
16:741-742.
2015
-
Polypharmacy in patients with advanced cancer and the role of medication discontinuation..
16:e333-e341.
2015
-
Response assessment criteria for brain metastases: proposal from the RANO group..
16:e270-e278.
2015
-
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study..
16:686-694.
2015
-
Accepting risk in the acceleration of drug development for rare cancers..
16:e190-e194.
2015
-
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial..
15:1263-1268.
2014
-
Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort..
15:841-851.
2014
-
Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?.
15:e251-e252.
2014
-
Addressing overdiagnosis and overtreatment in cancer: a prescription for change..
15:e234-e242.
2014
-
Does comparative effectiveness research promote rationing of cancer care?.
15:e132-e138.
2014
-
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial..
14:1307-1316.
2013
-
Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group..
14:e621-e629.
2013
-
Counting the costs of cancer care..
14:1142-1143.
2013
-
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis..
14:1200-1207.
2013
-
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial..
14:999-1008.
2013
-
Personalisation of colorectal cancer screening..
14:673-675.
2013
-
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data..
14:619-626.
2013
-
ACT II: treatment of anal cancer comes full circle..
14:443-445.
2013
-
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study..
14:354-362.
2013
-
New drugs for children and adolescents with cancer: the need for novel development pathways..
14:e117-e124.
2013
-
Quality of life in ICON7: need for patients' perspectives..
14:183-185.
2013
-
The limitations of imaging response criteria..
13:1064-1065.
2012
-
Abdominal radiation and diabetes: one more piece in the puzzle..
13:961-962.
2012
-
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial..
13:696-706.
2012
-
The STAMPEDE trial and celecoxib: how to adapt?.
13:443-445.
2012
-
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies..
13:385-394.
2012
-
Consensus-based standards for best supportive care in clinical trials in advanced cancer..
13:e77-e82.
2012
-
Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?.
12:723-724.
2011
-
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis..
11:653-660.
2010
-
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study..
10:581-588.
2009
-
Targeting the future in head and neck cancer..
10:204-205.
2009
-
Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations..
9:757-765.
2008
-
Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions..
9:596-599.
2008
-
Shared care of adult survivors of childhood cancers..
9:191-193.
2008
-
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data..
8:994-1000.
2007
-
Prostate cancer treatment unblinded..
13:567-568.
2012